Making sense of therapeutics using antisense technology

Bibliography

• Elbashir SM, Harborth J, Lendeckel W, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
   PubMed Web of Science ®Google Scholar
• Kruger K, Grabowski PJ, Zaug AJ, Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982;31:147-57
   PubMed Web of Science ®Google Scholar
• Lundblad EW, Altman S. Inhibition of gene expression by RNase P. Nat Biotechnol 2010;27:212-21
   Google Scholar
• Lavorgna G, Dahary D, Lehner B, In search of antisense. Trends Biochem Sci 2004;29:88-94
   PubMed Web of Science ®Google Scholar
• Lindberg J, Lundeberg J. The plasticity of the mammalian transcriptome. Genomics 2010;95:1-6
   PubMed Web of Science ®Google Scholar
• Werner A, Swan D. What are natural antisense transcripts good for? Biochem Soc Trans 2010;38:1144-9
   PubMed Web of Science ®Google Scholar
• Su WY, Xiong H, Fang JY. Natural antisense transcripts regulate gene expression in an epigenetic manner. Biochem Biophys Res Commun 2010;396:177-81
   PubMed Web of Science ®Google Scholar
• Rossignol F, Vache C, Clottes E. Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene 2002;299:135-40
   PubMed Web of Science ®Google Scholar
• Kimura T, Shiwen J, Nishizawa M, A natural antisense transcript of interferon-alpha1 gene regulates viral infection-mediated mRNA expression level and further induction of interferon-alpha1 protein. Cytokine 2009;48:124
   Web of Science ®Google Scholar
• Smalheiser NR, Lugli G, Torvik VI, Natural antisense transcripts are co-expressed with sense mRNAs in synaptoneurosomes of adult mouse forebrain. Neurosci Res 2008;62:236-9
   PubMed Web of Science ®Google Scholar
• Kurihara N, Hiruma Y, Yamana K, Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011;13:23-34
   PubMed Web of Science ®Google Scholar
• Hadad N, Tuval L, Elgazar-Carmom V, Endothelial ICAM-1 protein induction is regulated by cytosolic phospholipase A2alpha via both NF-kappaB and CREB transcription factors. J Immunol 2011;186:1816-27
   PubMed Web of Science ®Google Scholar
• Malik R, Roy I. Design and development of antisense drugs. Expert Opin Drug Discov 2008;3:1189-207
   PubMed Web of Science ®Google Scholar
• Bunka DH, Platonova O, Stockley PG. Development of aptamer therapeutics. Curr Opin Pharmacol 2010;10:557-62
   PubMed Web of Science ®Google Scholar
• Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 1988;85:5011-15
   PubMed Web of Science ®Google Scholar
• Borchelt D, Perdue ML. Influence of base-pairing in the leader region on in vitro translation of Rous sarcoma virus RNA. Virus Res 1985;3:141-51
   PubMed Web of Science ®Google Scholar
• Alotte C, Martin A, Caldarelli SA, Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro. Antiviral Res 2008;80:280-7
   PubMed Web of Science ®Google Scholar
• Kumar M, Carmichael GG. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc Natl Acad Sci USA 1997;94:3542-7
   PubMed Web of Science ®Google Scholar
• Werner A, Berdal A. Natural antisense transcripts: sound or silence? Physiol Genomics 2005;23:125-31
   PubMed Web of Science ®Google Scholar
• Mattes J, Yang M, Foster PS. Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specific regulation of gene function? Am J Respir Cell Mol Biol 2007;36:8-12
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005;438:685-9
   PubMed Web of Science ®Google Scholar
• Flores-Aguilar M, Besen G, Vuong C, Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis 1997;175:1308-16
   PubMed Web of Science ®Google Scholar
• Steininger C. Novel therapies for cytomegalovirus disease. Recent Pat Antiinfect Drug Discov 2007;2:53-72
   PubMedGoogle Scholar
• Menke J, Bork T, Kutska B, Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int 2011;79:452-63
   PubMed Web of Science ®Google Scholar
• Ansari MA, Dhar M, Muthukrishnan V, Administration of antisense oligonucleotides to Galpha(Q/11) reduces the severity of murine lupus. Biochimie 2003;85:627-32
   PubMed Web of Science ®Google Scholar
• Jacobson JD. Gonadotropin-releasing hormone: potential role in autoimmunity. Int Immunopharmacol 2001;1:1077-83
   PubMed Web of Science ®Google Scholar
• Diaz-Gallo L, Gourh P, Broen J, Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011;70:454-62
   PubMed Web of Science ®Google Scholar
• Delogu LG, Magrini A, Bergamaschi A, Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. Bioconjug Chem 2009;20:427-31
   PubMed Web of Science ®Google Scholar
• Sussman JD, Argov Z, McKee D, Antisense treatment for myasthenia gravis: experience with monarsen. Ann NY Acad Sci 2008;1132:283-90
   PubMed Web of Science ®Google Scholar
• Hong HJ, Jin SE, Park JS, Accelerated wound healing by smad3 antisense oligonucleotides-impregnated chitosan/alginate polyelectrolyte complex. Biomaterials 2008;29:4831-7
   PubMed Web of Science ®Google Scholar
• Ugarte M, Aguado C, Desviat LR, Propionic and methylmalonic acidemia: Antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet 2007;81:1262-70
   PubMed Web of Science ®Google Scholar
• Perez B, Rodriguez-Pascau L, Vilageliu L, Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J Inherit Metab Dis 2010;33:397-403
   PubMed Web of Science ®Google Scholar
• Zhou SH, Fan J, Chen XM, Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009;31:1624-33
   PubMed Web of Science ®Google Scholar
• Zhao FJ, Zhang SL, Ma L, Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer Ishikawa cell lines. Eur J Gynaecol Oncol 2009;30:54-9
   PubMed Web of Science ®Google Scholar
• Available from: www.avibio.com
   Google Scholar
• Chi KN, Eisenhauer E, Fazli L, A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96
   PubMed Web of Science ®Google Scholar
• Chi KN, Siu LL, Hirte H, A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-9
   PubMed Web of Science ®Google Scholar
• Olivares J, Kumar P, Yu Y, Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011;17:183-92
   PubMed Web of Science ®Google Scholar
• Bosch FX, Manos MM, Munoz N, Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802
   PubMed Web of Science ®Google Scholar
• Wang W, Sima N, Kong D, Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo. Cancer Lett 2010;291:67-75
   PubMed Web of Science ®Google Scholar
• Lee S, Kim JH, Kim H, Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expressionof interleukin-32 controls the expression of the humanpapillomavirus oncogene. Immunology 2011;132:410-20
   PubMed Web of Science ®Google Scholar
• Warren TK, Warfield KL, Wells J, Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16:991-4
   PubMed Web of Science ®Google Scholar
• Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002;196:1381-6
   PubMed Web of Science ®Google Scholar
• Ripple MJ, You D, Honnegowda S, Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J Immunol 2010;185:4804-11
   PubMed Web of Science ®Google Scholar
• Qureshi A, Zheng R, Parlett T, Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochem J 2006;394:511-18
   PubMed Web of Science ®Google Scholar
• Bell DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011;20:265-72
   PubMed Web of Science ®Google Scholar
• Akdim F, Visser ME, Tribble DL, Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1413-19
   PubMed Web of Science ®Google Scholar
• Trial watch. Antisense agent reduces LDL-cholesterol levels in high-risk patients. Nat Rev Drug Discov 2010;9:10
   Web of Science ®Google Scholar
• Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 2011;15:157-68
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lemonidis KM, Whipple CP, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-7
   PubMed Web of Science ®Google Scholar
• Gupta N, Fisker N, Asselin MC, A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010;5:e10682
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A, van Ommen GJ. Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 2010;18:146-53
   PubMed Web of Science ®Google Scholar
• Rimessi P, Fabris M, Bovolenta M, Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudo-exon responsible for X-linked dilated cardiomyopathy. Hum Gene Ther 2010;21:1137-46
   PubMed Web of Science ®Google Scholar
• Wheeler TM, Lueck JD, Swanson MS, Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007;117:3952-7
   PubMed Web of Science ®Google Scholar
• Kelley NW, Huang X, Tam S, The predicted structure of the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. J Mol Biol 2009;388:919-27
   Google Scholar
• Cattaneo E, Rigamonti D, Goffredo D, Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001;24:182-8
   PubMed Web of Science ®Google Scholar
• Gagnon KT, Pendergraff HM, Deleavey GF, Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 2010;49:10166-78
   PubMed Web of Science ®Google Scholar
• Zhang L, Leibowitz MJ, Zhang Y. Antisense oligonucleotides effectively inhibit the co-transcriptional splicing of a Candida group I intron in vitro and in vivo: implications for antifungal therapeutics. FEBS Lett 2009;583:734-8
   PubMed Web of Science ®Google Scholar
• Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci 2011;100:38-52
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38
   PubMed Web of Science ®Google Scholar
• Zhao X, Pan F, Holt CM, Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 2009;6:673-86
   PubMed Web of Science ®Google Scholar
• Li Q, Yuan F, Zhou C, Free-radical ring closure to conformationally locked alpha-L-carba-LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H. J Org Chem 2010;75:6122-40
   PubMed Web of Science ®Google Scholar
• Winkler J, Gilbert M, Kocourkova A, 2′-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA. ChemMedChem 2008;3:102-10
   PubMed Web of Science ®Google Scholar
• Zhang X, Koh CG, Yu B, Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide G3139 in a murine k562 xenograft model. Pharm Res 2009;26:1516-24
   PubMed Web of Science ®Google Scholar
• Mehiri M, Upert G, Tripathi S, An efficient biodelivery system for antisense polyamide nucleic acid (PNA). Oligonucleotides 2008;18:245-56
   PubMed Web of Science ®Google Scholar
• Hatamoto M, Ohashi A, Imachi H. Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 2010;86:397-402
   PubMed Web of Science ®Google Scholar
• Khatsenko O, Morgan R, Truong L, Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev 2000;10:35-44
   PubMedGoogle Scholar
• Raoof AA, Ramtoola Z, McKenna B, Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 2002;17:131-8
   PubMed Web of Science ®Google Scholar
• Raoof AA, Chiu P, Ramtoola Z, Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci 2004;93:1431-9
   PubMed Web of Science ®Google Scholar
• Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci 2008;97:225-36
   PubMed Web of Science ®Google Scholar
• Bantel-Schaal U. Integration of adeno-associated virus 2 DNA in human MKR melanoma cells induces a peptide with oncosuppressive properties. Int J Cancer 2001;92:537-44
   PubMed Web of Science ®Google Scholar
• Denti MA, Incitti T, Sthandier O, Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 2008;19:601-8
   PubMed Web of Science ®Google Scholar
• Sun X, Jiang H, Jiang X, Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther 2009;20:314-24
   PubMed Web of Science ®Google Scholar
• Williams KJ, Telfer BA, Xenaki D, Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005;75:89-98
   PubMed Web of Science ®Google Scholar
• Brown CY, Sadlon T, Gargett T, Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector. Hum Gene Ther 2010;21:1005-17
   PubMed Web of Science ®Google Scholar
• Ravina M, Paolicelli P, Seijo B, Knocking down gene expression with dendritic vectors. Mini Rev Med Chem 2010;10:73-86
   PubMed Web of Science ®Google Scholar
• Wang P, Zhao XH, Wang ZY, Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. Cancer Lett 2010;298:34-49
   PubMed Web of Science ®Google Scholar
• Ljubimova JY, Lakhter AJ, Loksh A, Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res 2001;61:5601-10
   PubMed Web of Science ®Google Scholar
• Ding H, Inoue S, Ljubimov AV, Inhibition of brain tumor growth by intravenous poly(beta-L-malic acid) nanobioconjugate with pH-dependent drug release. Proc Natl Acad Sci USA 2010;107:18143-8
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Saad M, Pozharov VP, Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010;107:10737-42
   PubMed Web of Science ®Google Scholar
• Ozbas-Turan S, Akbuga J, Sezer AD. Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats. Oligonucleotides 2010;20:147-53
   PubMed Web of Science ®Google Scholar
• Elhamess H, Bertrand JR, Maccario J, Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles. Oligonucleotides 2009;19:255-64
   PubMed Web of Science ®Google Scholar
• Hagigit T, Abdulrazik M, Orucov F, Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release 2010;145:297-305
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32
   PubMed Web of Science ®Google Scholar
• Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000;5:521-32
   PubMed Web of Science ®Google Scholar
• Berthold PR, Shiraishi T, Nielsen PE. Cellular delivery and antisense effects of peptide nucleic acid conjugated to polyethyleneimine via disulphide linkers. Bioconjug Chem 2010;21:1933-8
   PubMed Web of Science ®Google Scholar
• Kang H, Alam MR, Dixit V, Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug Chem 2008;19:2182-8
   PubMed Web of Science ®Google Scholar
• Zou J, Qiao X, Ye H, Inhibition of ataxia-telangiectasia mutated by antisense oligonucleotide nanoparticles induces radiosensitization of head and neck squamous-cell carcinoma in mice. Cancer Biother Radiopharm 2009;24:339-46
   PubMed Web of Science ®Google Scholar
• Thomas SM, Ogagan MJ, Freilino ML, Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008;73:627-38
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Yu EY, Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247-54
   PubMed Web of Science ®Google Scholar
• Bilanges B, Stokoe D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 2005;388:573-83
   PubMed Web of Science ®Google Scholar
• Xie SY, Ren ZR, Zhang JZ, Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. Hum Mol Genet 2007;16:2616-25
   PubMed Web of Science ®Google Scholar
• Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassemias. In: Weatherall DJ, Clegg B, editors, The thalassemia syndromes. 4th edition. Blackwell Science, Oxford; 2001. p. 133-91
   Google Scholar
• Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004;5:355-65
   PubMed Web of Science ®Google Scholar
• Williams BR. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation. Biochem Soc Trans 1997;25:509-13
   PubMed Web of Science ®Google Scholar
• Player MR, Torrence PF. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 1998;78:55-113
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4:457-67
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200
   PubMed Web of Science ®Google Scholar
• Chi JT, Chang HY, Wang NN, Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 2003;100:6343-6
   PubMed Web of Science ®Google Scholar
• Sledz CA, Holko M, de Veer MJ, Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9
   PubMed Web of Science ®Google Scholar
• Availaible from: www.isip.com
   Google Scholar
• Availaible from: www.genzyme.com
   Google Scholar
• Tamm I. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer. Curr Opin Investig Drugs 2008;9:638-46
   PubMed Web of Science ®Google Scholar
• Availaible from: www.antisense-pharma.de
   Google Scholar
• Bogdahn U, Hau P, Stockhammer G, Targeted therapy for high-grade glioma with the TGF-{beta}2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neurooncol 2010;13:132-42
   Google Scholar
• Available from: www.tevapharm.com
   Google Scholar
• Available from: www.oncogenex.ca
   Google Scholar
• Available from: www.bms.com
   Google Scholar
• Available from: www.excaliard.com
   Google Scholar
• Available from: www.lilly.com
   Google Scholar
• Available from: www.enzo.com
   Google Scholar
• Plummer R, Vidal L, Griffin M, Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 2009;15:3177-83
   PubMed Web of Science ®Google Scholar
• Dong L, Xia S, Chen H, Spleen-specific suppression of TNF-alpha by cationic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal models. Biomaterials 2009;30:4416-26
   PubMed Web of Science ®Google Scholar
• Wang J, Tao X, Zhang Y, Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials 2010;31:4426-33
   PubMed Web of Science ®Google Scholar
• Wei B, Wei Y, Zhang K, Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed Pharmacother 2009;63:313-18
   PubMed Web of Science ®Google Scholar
• Koppelhus U, Shiraishi T, Zachar V, Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjug Chem 2008;19:1526-34
   PubMed Web of Science ®Google Scholar
• Pillai VC, Yesudas R, Shaik IH, Delivery of NADPH-cytochrome P450 reductase antisense oligos using avidin-biotin approach. Bioconjug Chem 2010;21:203-7
   PubMed Web of Science ®Google Scholar
• Yin H, Moulton HM, Betts C, A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009;18:4405-14
   PubMed Web of Science ®Google Scholar